Sirona Biochem Appoints Michael Rogers to Board of Directors

Sirona Biochem Appoints Michael Rogers to Board of Directors

VANCOUVER, BRITISH COLUMBIA--(Marketwire - December 10, 2010) - Sirona Biochem Corp. (TSX VENTURE: SBM) (the "Company"), a biotechnology company specializing in carbohydrate-based molecules, including therapeutics for diabetes and obesity, cosmeceuticals and biological ingredients, announced today that it has appointed Michael Rogers to its Board of Directors. Mr. Rogers is currently President of Palmer Rogers Encore Ventures.

"Mike Rogers' more than 25 years of experience as a highly respected business leader in the investment industry will be valuable in helping Sirona Biochem secure funding to support the development of our three carbohydrate-based programs," said Mark Senner, President of Sirona Biochem. "We have developed an innovative chemistry technique that we feel enhances drug qualities. Attracting strong business leaders such as Mike Rogers will help to ensure we maximize on the potential of our programs," he added.

About Michael Rogers

Michael Rogers is an accomplished business executive with more than 25 years of progressive experience in the investment industry. Currently, Mr. Rogers is President of Palmer Rogers Encore Ventures, a company he co-founded with business partner and advertising leader, Frank Palmer. Prior to co-founding Palmer Rogers, Mr. Rogers held several leadership roles including Vice-President at Canaccord Capital and Senior Vice-President at Yorkton Securities. Previously, he also played a significant role in building the Bank of British Columbia to a major banking operation. In addition to his professional accomplishments, Mr. Rogers is deeply rooted in the local community and has served on the board of the Whistler Land Corporation, Whistler Resort Association and several charitable organizations.

About Sirona Biochem Corp.

Sirona Biochem is a biotechnology company developing diabetes and obesity therapeutics, anti-aging cosmetic ingredients and biological ingredients. Our proprietary chemistry expertise is being applied towards the development of these carbohydrate-based programs. Our aim is to improve the commercial value of carbohydrate-based molecules by improving their pharmaceutical qualities. In August 2010, Sirona Biochem announced it had signed a binding preliminary agreement to acquire France-based TFChem. For more information visit

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements. 

Sirona Biochem Corp.
Julie Jang
Director, Communications
604.641.4466 x273
[email protected]